curasan AG, listed in the General Standard of the German Stock Exchange, has signed an agreement which provides Zimmer Dental Inc, Carlsbad, CA, (USA) with exclusive global distribution rights. - July 27, 2011
curasan AG has received FDA certification for its new granular bone regeneration material Ceracell® Dental - May 07, 2011
curasan AG has received European approval for a novel synthetic bone regeneration material. - March 30, 2011
curasan AG has received FDA certification and, therefore, marketing authorization throughout the USA of the synthetic bone replacement material Osbone® Dental which already has been authorized in the EU as Osbone®. - February 12, 2011
curasan AG has signed an agreement with Stryker S.A., Montreux, Switzerland, to sell and market bone replacement and regeneration materials for different orthopedic indications - February 11, 2011
curasan Inc., the north American subsidiary of exchange listed curasan AG, Germany, (ISIN: DE 000 549 453 8), has signed an exclusive supply agreement with TransCorp Spine Inc., Michigan, USA, for Cerasorb® Ortho block forms used to repair vertebral bone channels created during surgeries to decompress... - January 13, 2011
curasan AG has received the certification for the synthetic bone regeneration material Cerasorb® M ORTHO from the Canadian authorities, Health Canada. - November 20, 2010
curasan AG has received European approval for its new granular bone regeneration material Ceracell® - October 23, 2010
curasan AG expects to make a considerable profit instead of the two million euro loss announced for the financial year 2010. - October 06, 2010
Supporting wound healing and tissue regeneration through the extraction of autologous platelet-mediator-concentrate (PMC) – high patient compatibility using autologous blood – No need for centrifuges and external laboratories. - July 29, 2010
curasan AG has concluded a contract with Matricel GmbH, Herzogenrath, which secures exclusive rights for both companies over a jointly developed new product line. - May 27, 2010
curasan AG, listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), was able to achieve an annual surplus of 0.2 million Euro in the fiscal year 2009. The performance per share amounted to 0.03 Euro.
“We had originally expected a slight negative performance for 2009... - May 08, 2010
In Germany alone, every year about 800,000 tooth implants are placed. In the case of almost every second patient bone augmentation is necessary, because the jawbone atrophy is already too advanced. The development of bone substitute materials has advanced considerably over the last few years, particularly... - March 18, 2010
curasan AG, listed in the General Standard of the Deutsche Börse AG, is commencing the sale, through a subsidiary, of its synthetic bone regeneration material Cerasorb® M Ortho in the United States. - February 20, 2010
A new study was presented at the 4th Annual Congress of the German Spine Society in Munich – it demonstrated the long-term effect of Curavisc® in the treatment of chronic facet syndrome - December 16, 2009
curasan AG has received CE certification and, therefore, marketing authorization throughout Europe of the synthetic bone replacement material Osbone®. - December 12, 2009
curasan AG, which is listed on the General Standard of the German Stock Exchange, has signed a research and development agreement with the Ben-Gurion University of the Negev (BGU), Israel. - November 19, 2009
curasan AG has received CE certification and, therefore, marketing authorization for the ATR® (Advanced Tissue Regeneration) product. - October 18, 2009
curasan AG is to invest in its future growth by implementing a technological investment programme amounting to approximately 1 million euros, despite the current crisis in the financial markets - October 14, 2009
curasan AG, listed on the General Standard of Deutsche Börse AG as ISIN: DE 000 549 453 8, has just received a grant of €1.48 million from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) for a bone regeneration research project... - September 16, 2009
